Investors double down on AI drug development
Funding for artificial intelligence (AI) in drug development hit $4.1 billion in 2021, a 36% increase from the year before, according to Emersion Insights. The AI drug development industry has gained a lot of attention from investors, venture capital firms, and corporate investment funds in recent years. Read More
SQZ Biotechnologies receives FDA clearance of IND for cancer cell therapy
SQZ Biotechnologies announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for SQZ-eAPC-HPV, authorizing the company to proceed with initiating a phase I/II clinical trial of the novel cell therapy candidate. Read More
Eikonoklastes bolsters pipeline
Eikonoklastes Therapeutics has completed a license agreement with the University of California, San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases, including a potential treatment for Lou Gehrig's disease, or amyotrophic lateral sclerosis. Read More
64x Bio gains funding to advance cell line engineering platform
64x Bio, a synthetic biology company, announced the close of a $55 million series A financing round to fund the expansion of VectorSelect, the company's cell line engineering platform. Read More
ONI closes $75M series B funding
ONI, known for the Nanoimager microscopy platform, closed a $75 million series B financing round. The proceeds will be used to grow ONI's commercial and R&D teams in the U.S. and Asia, driving technology adoption in those geographies. Read More
Targeted nanoparticle delivery provides boost for diabetes transplant
Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects. Read More
Center for Breakthrough Medicines partners with Univ. of Pennsylvania
The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's (UPenn) Gene Therapy Program are collaborating to share UPenn's knowledge and expertise in the development of gene therapies with CBM's manufacturing capacity and focus on advanced therapies. Read More
Altos Labs launches cellular rejuvenation programming
Altos Labs has launched as a new biotechnology company dedicated to unraveling the biology of cellular rejuvenation programming. Read More
Developments in cell therapy boost potential for autoimmune disease treatments
Healthcare leaders are working together to change the therapeutic landscape for autoimmune diseases, which are often due to unknown causes, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Atara Biotherapeutics, Kyverna Therapeutics, and the National Institutes of Health are a few organizations that are dedicated to finding treatments for patients with limited options. Read More
Ori Biotech gains funding for CGT platform
Ori Biotech has obtained over $100 million in an oversubscribed series B funding round. Ori said it will use the funds to further expand key personnel across all functions to prepare for the launch of its cell and gene therapy (CGT) manufacturing platform. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter